Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.Dental Auxiliaries: Personnel whose work is prescribed and supervised by the dentist.Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.Ibuprofen: A nonsteroidal anti-inflammatory agent with analgesic properties used in the therapy of rheumatism and arthritis.Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.Chills: The sudden sensation of being cold. It may be accompanied by SHIVERING.Dental Devices, Home Care: Devices used in the home by persons to maintain dental and periodontal health. The devices include toothbrushes, dental flosses, water irrigators, gingival stimulators, etc.Contusions: Injuries resulting in hemorrhage, usually manifested in the skin.Pharyngitis: Inflammation of the throat (PHARYNX).Pneumonia, Pneumocystis: A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.Pneumocystis: A genus of ascomycetous FUNGI, family Pneumocystidaceae, order Pneumocystidales. It includes various host-specific species causing PNEUMOCYSTIS PNEUMONIA in humans and other MAMMALS.CreatinineHIV Seropositivity: Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV).Etoposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Pneumocystis carinii: The prototype species of PNEUMOCYSTIS infecting the laboratory rat, Rattus norvegicus (RATS). It was formerly called Pneumocystis carinii f. sp. carinii. Other species of Pneumocystis can also infect rats.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.Drug Information Services: Services providing pharmaceutic and therapeutic drug information and consultation.Pamphlets: Printed publications usually having a format with no binding and no cover and having fewer than some set number of pages. They are often devoted to a single subject.Drug Labeling: Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.Patient Education as Topic: The teaching or training of patients concerning their own health needs.Formularies as Topic: Works about lists of drugs or collections of recipes, formulas, and prescriptions for the compounding of medicinal preparations. Formularies differ from PHARMACOPOEIAS in that they are less complete, lacking full descriptions of the drugs, their formulations, analytic composition, chemical properties, etc. In hospitals, formularies list all drugs commonly stocked in the hospital pharmacy.Drug Industry: That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.Medical Records Systems, Computerized: Computer-based systems for input, storage, display, retrieval, and printing of information contained in a patient's medical record.Advertising as Topic: The act or practice of calling public attention to a product, service, need, etc., especially by paid announcements in newspapers, magazines, on radio, or on television. (Random House Unabridged Dictionary, 2d ed)Computer Security: Protective measures against unauthorized access to or interference with computer operating systems, telecommunications, or data structures, especially the modification, deletion, destruction, or release of data in computers. It includes methods of forestalling interference by computer viruses or so-called computer hackers aiming to compromise stored data.Therapeutic Equivalency: The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Nuclear Reprogramming: The process that reverts CELL NUCLEI of fully differentiated somatic cells to a pluripotent or totipotent state. This process can be achieved to a certain extent by NUCLEAR TRANSFER TECHNIQUES, such as fusing somatic cell nuclei with enucleated pluripotent embryonic stem cells or enucleated totipotent oocytes. GENE EXPRESSION PROFILING of the fused hybrid cells is used to determine the degree of reprogramming. Dramatic results of nuclear reprogramming include the generation of cloned mammals, such as Dolly the sheep in 1997.Epigenesis, Genetic: A genetic process by which the adult organism is realized via mechanisms that lead to the restriction in the possible fates of cells, eventually leading to their differentiated state. Mechanisms involved cause heritable changes to cells without changes to DNA sequence such as DNA METHYLATION; HISTONE modification; DNA REPLICATION TIMING; NUCLEOSOME positioning; and heterochromatization which result in selective gene expression or repression.Inventions: A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.Lower Gastrointestinal Tract: The segment of GASTROINTESTINAL TRACT that includes the small intestine below the DUODENUM, and the LARGE INTESTINE.Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.Fibrocystic Breast Disease: A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.Intellectual Property: Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Search Engine: Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)Emergency Service, Hospital: Hospital department responsible for the administration and provision of immediate medical or surgical care to the emergency patient.Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)Dizziness: An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.Monoamine Oxidase Inhibitors: A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.Universal Precautions: Prudent standard preventive measures to be taken by professional and other health personnel in contact with persons afflicted with a communicable disease, to avoid contracting the disease by contagion or infection. Precautions are especially applicable in the diagnosis and care of AIDS patients.Hypertensive Retinopathy: Degenerative changes to the RETINA due to HYPERTENSION.Central Nervous System Depressants: A very loosely defined group of drugs that tend to reduce the activity of the central nervous system. The major groups included here are ethyl alcohol, anesthetics, hypnotics and sedatives, narcotics, and tranquilizing agents (antipsychotics and antianxiety agents).Phytotherapy: Use of plants or herbs to treat diseases or to alleviate pain.

Disposition and metabolism of pentamethylmelamine and hexamethylmelamine in rabbits and humans. (1/29)

The disposition and metabolism of pentamethylmelamine (PMM) and hexamethylmelamine (HMM) were studied in the rabbit, and the disposition of PMM was studied in humans. Parent compound and metabolites were identified by thin-layer chromatography, gas chromatography, and gas chromatography/mass spectrometry analyses. Plasma elimination in both species following i.v. administration of each drug was best described by a two-compartment open model. Both compounds were extensively demethylated with less than 1% of the total dose administered recovered in the urine over 24 hr. The areas under the plasma time-concentration curves of PMM and HMM following p.o. administration to rabbits were 5 and 25% of the areas following i.v. administration. Gastrointestinal absorption was rapid and efficient with 75 to 89% of drug equivalents recoverable in the urine after p.o. administration of [ring-14C]PMM or [ring-14C]HMM to rabbits. Reduced bioavailability of PMM and HMM p.o. appears to be a consequence of rapid metabolism presumably in the liver.  (+info)

Recurrent ovarian cancer: how important is it to treat to disease progression? (2/29)

Ovarian cancer is increasingly recognized as a chronic disease whose treatment is often characterized by administration of multiple, sequential active agents, each of which may or may not be accompanied by a tumor response. Despite the large proportion of patients who relapse and undergo longer-term treatment, the question of optimal treatment duration has not been fully addressed to date. For patients who progress on therapy, the answer is straightforward: they are switched to another active agent, presumably having a different mechanism of action from previous therapies with, ideally, limited overlapping toxicities. However, for patients who remain in partial response or who have stable disease, the answer is less apparent and less clear. The majority of oncologists believe that treatment beyond 6 cycles of a given therapy does not provide any additional benefit to patients. There are some data to support that treatment strategy. However, with the advent of new, less toxic agents, treatment to progression should be further explored. Agents that are potentially well suited for extended treatment intervals may include such properties as absence of cumulative toxicity, non-cross-resistance, positive benefit on quality of life, and convenient schedule. A number of active agents in ovarian cancer (platinum, paclitaxel, topotecan, liposomal doxorubicin, docetaxel, gemcitabine, and etoposide) will be reviewed in the context of what is known about cumulative toxicity, potential adverse effects on patients' quality of life, and evidence addressing the potential benefits of longer-term treatment.  (+info)

Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. (3/29)

PURPOSE: A previous report suggested the nadir serum CA-125 level within the group of patients with ovarian cancer who achieved normalization of CA-125 accurately defined the risk of relapse. Using similar CA-125 subgroups, we sought to determine if the baseline CA-125 level before initiation of maintenance chemotherapy in women achieving a clinically-defined complete response to primary chemotherapy would be of prognostic value. PATIENTS AND METHODS: Patients included in this retrospective analysis had been treated on one of two previously reported trials of maintenance chemotherapy (three v 12-monthly cycles of paclitaxel; oral altretamine), with a baseline CA-125 level of < or = 35 u/mL. Progression-free survival (PFS) from study entry was analyzed by the Cox regression model. RESULTS: The distribution of premaintenance baseline CA-125 levels for the 384 patients was 58%, 34%, and 8% for values of (A) < or = 10 u/mL, (B) 11 to 20 u/mL, and (C) 21 to 35 u/mL, respectively. The baseline CA-125 was highly statistically significant, either as a categoric variable (P < .001) or as a continuous variable (P < .0001). Median PFS was 24 months, 17 months, and 7 months for groups (A), (B), and (C), respectively. There was no evidence the CA-125 effect differed by trial or treatment in an interaction analysis (P = .70). CONCLUSION: The baseline CA-125 level before initiation of maintenance chemotherapy strongly predicts the risk of subsequent relapse. Patients with premaintenance baseline CA-125 values < or = 10 u/mL have a superior PFS compared with higher levels in the normal CA-125 range.  (+info)

Relationship between frailty and cognitive decline in older Mexican Americans. (4/29)

 (+info)

Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer. (5/29)

Forty-six patients with recurrent ovarian cancer were reoperated, and cancer samples for the subrenal capsule assay (SRCA) were collected from 23 of them, whereas this test was not done in the remaining 23 control patients. The SRCA was evaluable in 22 cases (96%). Taken together, no significant difference appeared in the 3 years' survival figures between the groups: seven of 22 patients (32%) with the evaluable SRCA and six of 23 control patients (26%) were alive. However, a further analysis of the data revealed that the SRCA guided the selection of chemotherapy only in 15 patients, whereas tumour samples were resistant to all cytostatics tested in six cases and toxic side-effects limited the clinical application of the test results in the remaining one case. Four of the 11 patients (36%) whose further chemotherapy was strictly chosen based on the SRCA and seven of the 24 patients (29%) whose treatment was based on physician's choice survived at least 3 years. Our conclusion is that the SRCA is of limited value in the selection of second-line chemotherapy in recurrent ovarian cancer.  (+info)

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. (6/29)

Long-term follow-up was obtained on 726 women with advanced ovarian carcinoma (suboptimal stage III and stage IV) who had received primary chemotherapy on two Gynecologic Oncology Group (GOG) protocols between 1976 and 1982. The first study compared melphalan alone versus melphalan plus hexamethylmelamine versus cyclophosphamide plus doxorubicin (CA). The second study evaluated the same CA regimen with or without cisplatin. Eligibility for the two studies was the same. At last contact, 76 patients were alive. In a multivariate analysis, cell type other than clear cell or mucinous, cisplatin-based treatment, good performance status, younger age, lower stage, clinically nonmeasurable disease, smaller residual tumor volume, and absence of ascites were favorable characteristics for overall survival (P less than .05). Second-look laparotomy was negative significantly more often among those with endometrioid tumors; there were no negative second-look laparotomies among those with mucinous or clear cell tumors. There were 30 patients with suboptimal stage III disease who had a negative second-look laparotomy; 18 (60%) have experienced recurrence, and 13 (43%) have died. Although cisplatin treatment was beneficial, new treatments are clearly needed.  (+info)

Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy. (7/29)

 (+info)

Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). (8/29)

The data on 914 patients enrolled in four randomised trials in advanced ovarian cancer, consecutively conducted by the same cooperative group between 1978 and 1986, were analysed with the aims of: (1) determining the impact of selected prognostic variables on survival; (2) finding, from the interaction of favourable prognostic factors and treatment, an approximate estimate of the magnitude of the survival advantage associated with the use of platinum-based combination chemotherapy. The overall 3-year survival in this series of patients is twice that reported historically (22%; 95% CL 18.7-25.4). The proportional hazard regression model was used to perform the analysis on survival. Residual tumour size, age, FIGO stage and cell type were all independent determinants of survival. Differences in survival from the various prognostic groups were impressive with 5-year survival rates ranging from 7 to 62%. However, these differences were not qualitative (i.e. the kinetics of survival were similar for the best and the worst groups) suggesting that current prognostic factors are of little use for selecting 'biologically' different sub-populations. Platinum-based regimens were associated to an overall prolonged median survival, but this benefit was not observable in the subgroup with most favourable prognosis (less than 2 cm residual tumour size). The implications of these observations for clinical research and ovarian cancer patients care are discussed.  (+info)

*Altretamine

... (trade name Hexalen) is an antineoplastic agent. It was approved by the U.S. FDA in 1990. It is indicated for use ... Malik IA (2001). "Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer". Jpn. J ... ISBN 978-0-7817-6879-5. Drugs.com: Altretamine Monograph Wiernik, P. H.; Yeap, B.; Vogl, S. E.; Kaplan, B. H.; Comis, R. L.; ... The precise mechanism by which altretamine exerts its anti-cancer effect is unknown but it is classified by MeSH as an ...

*Triethylenemelamine

Altretamine Luippold HE, Gooch PC, Brewen JG (February 1978). "The production of chromosome aberrations in various mammalian ...

*Eisai (company)

This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer ...

*List of drugs: Al

... altretamine (INN) altumomab (INN) Alu-Cap Alu-Tab Aludrox aluminium clofibrate (INN) Alupent (Boehringer Ingelheim) Alustra ...

*List of MeSH codes (D03)

... altretamine MeSH D03.383.931.190 --- apazone MeSH D03.383.931.247 --- atrazine MeSH D03.383.931.320 --- ferrozine MeSH D03.383. ...

*Alkylating antineoplastic agent

... procarbazine altretamine Some sources explicitly exclude the triazenes (dacarbazine, mitozolomide, temozolomide) from the ...

*ATC code L01

Binimetinib L01XE42 Ribociclib L01XE43 Brigatinib QL01XE91 Toceranib L01XX01 Amsacrine L01XX02 Asparaginase L01XX03 Altretamine ...

*Index of oncology articles

... altretamine - aluminium sulfate - ALVAC-CEA vaccine - Amanita phalloides - Ambien - amelanotic melanoma - Ames, Bruce - ...

*DMOZ - Health: Pharmacy: Drugs and Medications: A

February 1, 2017 at 11:15:03 UTC ...
DISEASE CHARACTERISTICS: Documented HIV antibody positive Histologically confirmed, by biopsy, non-Hodgkins lymphoma that is in complete remission or stable/partial remission for a minimal period of one month And/or Histologically confirmed, by biopsy, Kaposis sarcoma without stable disease. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Hematopoietic: Absolute neutrophil count at least 500/mm3 Platelet count greater than 25,000/mm3 (unless secondary to lymphoma) Hepatic: Transaminases less than 5 times upper limit of normal AND Bilirubin less than 2.0, unless secondary to lymphoma Renal: Creatinine less than 2.0 mg/dL OR Creatinine clearance at least 60 mL/min Dose reduction of 21% if creatinine clearance 10-50 mL/min Dose reduction of 50% if creatinine clearance less than 10 mL/min Cardiovascular: No active cardiac arrhythmia or angina Pulmonary: Must exclude Pneumocystis carinii pneumonia if there is any suspicion of infection Other: No uncontrolled ...
Visit your doctor for checks on your progress.. This drug may make you feel generally unwell. This is not uncommon, as chemotherapy can affect healthy cells as well as cancer cells. Report any side effects. Continue your course of treatment even though you feel ill unless your doctor tells you to stop.. Call your doctor or health care professional for advice if you get a fever, chills or sore throat, or other symptoms of a cold or flu. Do not treat yourself. This drug decreases your bodys ability to fight infections. Try to avoid being around people who are sick.. This medicine may increase your risk to bruise or bleed. Call your doctor or health care professional if you notice any unusual bleeding.. Be careful brushing and flossing your teeth or using a toothpick because you may get an infection or bleed more easily. If you have any dental work done, tell your dentist you are receiving this medicine.. Avoid taking products that contain aspirin, acetaminophen, ibuprofen, naproxen, or ketoprofen ...
Doctors give unbiased, helpful information on indications, contra-indications, benefits, and complications: Dr. Romero on chemo bandanas: Choosing chemo depends on many factors, so only your doctor can decide what might work for you. Drugs you havent mentioned include altretamine, capecitabine, cytoxan, (cyclophosphamide) vinorelbine, ifosfamide, etoposide, and irinotecan. There are also several hormonal agents. And a clinical trial might be an option. Check out www.Cancer.Gov for more info. And good luck.
0108]Other second agents include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; ...
0092]Other anti-cancer drugs include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; ...
This is a 48 week study for HIV-infected patients who have failed several regimens including PIs, NNRTs and NRTIs. Patients will be randomly selected to be in 1 of 4 groups. Three of the 4 groups will contain capravirine in different doses combined with Kaletra and nucleosides and one of the groups will be a combination of Kaletra and nucleosides without the capravirine ...
Title. Comparing the Effectiveness of Different Drug Combinations for Advanced Cancer of the Urothelium Which Cannot Be Controlled With Surgery (A Phase III Trial). Sponsor. Eastern Cooperative Oncology Group through the NCI-sponsored Cancer Cooperative Group Program. Purpose of the Study. To slow, stop or decrease the growth of cancer of the urothelium and to compare and evaluate the effectiveness of the two drug treatments. The two treatments were; 1) a Two-Drug (paclitaxel and carboplatin) Combination Chemotherapy, and 2) a Four-Drug (methotrexate, vinblastine, asplatin, doxorubin) Combination Chemotherapy. The urothelium is the lining of the kidney, ureter, bladder, or lining of the urinary tract.. Results. The study did not show one treatment to be more beneficial than the other. Of patients receiving the four-drug combination, 12.8 percent experienced a complete response rate (no detectable cancer remaining) and 23.1 percent experienced a decrease in the size or extent of their cancer ...
The Challenges of Risk Perception and Infectious Disease Response: Counteracting Inaccurate Risk Perception is a research paper published by the Scowcroft Institute of International Affairs at the Bush School of Government and Public Service at Texas A&M University.
Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: A cancer and leukemia group B study. Journal of Clinical Oncology. 1983 ...
This case illustrates the choices that must be made between a number of primary therapies for a newly diagnosed MM patient and how these choices have an impact on further treatment when the patient relapses. A variety of 2- and 3-drug combinations are currently available as primary treatment for transplantation-eligible MM patients.1 In the case discussed here, Mr. M was placed on the combination of bortezomib, lenalidomide, and dexamethasone, a regimen that includes a proteasome inhibitor and an immunomodulatory agent, two drug classes that are active in MM. A recent phase II study in 140 previously untreated MM patients compared three- and four-drug combinations of bortezomib, lenalidomide, dexamethasone, and cyclophosphamide, all followed by bortezomib maintenance. The combination of bortezomib, lenalidomide, and dexamethasone resulted in a ≥very good response rate of 51% and a 1-year progression-free survival (PFS) of 83%, whereas bortezomib, cyclophosphamide, and dexamethasone, another ...
Animal Disease Response Training provides the critical information needed to minimize the affects of an outbreak on your community. Responders to whom this
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Thirty-two patients with epithelial carcinoma of the ovary underwent a second-look laparotomy after the completion of an average of 18 courses of adjuvant chemotherapy. Nine patients (28%) were found to have persistent disease. This low rate of positive second-look laparotomy is probably because these patients received chemotherapy for 18 months and in those patients whose tumour did not respond to the medication, the disease would progress and the patient died without becoming a candidate for laparotomy. There was no stage Ic patient whose second-look laparotomy was positive and the need for second-look laparotomy is questionable in such patients. Stage III/IV patients and patients with recurrence had a significantly higher positive second-look laparotomy rate than stage Ic/II patients, 44% and 7% respectively. In the present group of patients with positive tumour at second-look laparotomy, 33% responded to furtrher debulking operation and chemotherapy and remained disease free 15-33 months ...
The level of an individual protein in cells treated with combinations of drugs is best explained by simple linear superposition of the protein levels in response to single drugs. and protease inhibitors used to treat HIV contamination4 and the four-drug combination comprising DNA-damaging brokers a microtubule disruptor and a corticosteroid (cyclophosphamide doxorubicin vincristine and prednisone together known as CHOP) used to treat non-Hodgkins lymphoma5. Variations on these treatments exist SCH-527123 that add even more drugs to the mix. Given this SCH-527123 pattern one may ask: what is the most effective drug combination complexity and how will we know when we get there? In nature a bacterial endosymbiont growing around the antennae of certain wasp species releases a cocktail of nine different antibiotic compounds that together protect growing wasp larvae from a broad range of fungal and bacterial pathogens6. This suggests that we have much to SCH-527123 go before achieving the same ...
State and local officials in four Kansas counties are conducting an exercise to practice the states plan to respond to a foreign animal disease.
* Gileads once-daily quad pill to be sold as Stribild * Gilead to conduct further studies on safety, drug interactions * Shares unchanged after hours (Adds analyst comment, label information,
Researchers have identified lead compounds from Cuban sea anemone extract and the rue plant that may help treat autoimmune disease response in type-1 diabetes and rheumatoid arthritis. The compounds act by blocking the ion channel in autoimmune T lymphocytes and disabling these cells, while allowing other white blood cells to fight disease and infection.. In one set of tests using blood samples from type-1 diabetes patients and joint fluid from people with rheumatoid arthritis, the researchers found that both compounds suppressed the function of the autoimmune T-cells without affecting other T-cells that fight infections.. In another set of tests using rats, the compound from the rue shrub plant delayed the onset and reduced the incidence of disease in diabetic rats, while the venom compound stopped the progression of the disease and improved the joint function of rats with experimental autoimmune arthritis. In these rat tests, the compounds were nontoxic.. The study was published in the Nov. ...
The US Centers for Disease Control and Prevention (CDC) today released details about efforts to enhance disease detection in Uganda and Vietnam that could provide a model for helping other countries protect their citizens and the wider global community from health threats. In both instances, the CDC and its partners undertook 6-month missions that focused…
The purpose of this study is to determine the survival, disease response, and side effects of Tasigna® (nilotinib) in patients who have malignant gliom
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. We found that primary BPDCN cells were dependent on the antiapoptotic protein BCL2 and were uniformly sensitive to the BCL2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profiling. Animals bearing BPDCN patient-derived xenografts had disease responses and improved survival after venetoclax treatment in vivo. Finally, we report on 2 patients with relapsed/refractory BPDCN who received venetoclax off-label and experienced significant disease responses. We propose that venetoclax or other BCL2 inhibitors undergo expedited clinical evaluation in BPDCN, alone or in combination with other therapies. In addition, these data illustrate an example of precision medicine to predict treatment response using ex vivo functional assessment of primary tumor tissue, without requiring a genetic ...
Looking for online definition of second-look operation in the Medical Dictionary? second-look operation explanation free. What is second-look operation? Meaning of second-look operation medical term. What does second-look operation mean?
Maurie Markman, M.D. is the Vice President for Clinical Research at the University of Texas M.D. Anderson Cancer Center located in Houston, Texas. On June 6, 2008, Dr. Markman moderated an expert panel discussion entitled, Recognizing and Overcoming Challenges in the Treatment of Recurrent Ovarian Cancer. The panel discussion was recorded as a Continuing Medical…
LBD14063-03-6 A. 9281 2 matters related to the review of his or her report and shall vote on its acceptance or rejection only when there is a tie. Should the board fail to vote to either accept or reject the findings within thirty days of submission of such findings, or should the board accept the findings by the chief enforcement counsel that there is reasonable cause to believe that a violation warranting criminal prosecution has taken place, the chief enforcement counsel shall, forthwith, and in any event no later than seven calendar days of such failure to accept or reject the find- ings by the board, refer such matter to the attorney general or district attorney with jurisdiction over such matter to commence a criminal action as such term is defined in the criminal procedure law. PROVIDED, HOWEVER, WHERE REASONABLE CAUSE EXISTS TO BELIEVE THAT A CANDIDATE FOR THE OFFICE OF ATTORNEY GENERAL HAS VIOLATED ANY PROVISION OF THIS CHAP- TER, THE STATE BOARD SHALL REFER THE MATTER TO THE DISTRICT ...
The Food and Drug Administration (FDA) has approved Zejula (niraparib capsules; Tesaro) for the maintenance treatment of adults with recurrent epithelial o
The ontogeny and disease responses of Langerhans-like cells within lymphoid tissues of Atlantic salmon, Salmo salar, and rainbow trout, Oncorhynchus mykiss, were investigated. These cells were studied in situ with the use of two markers: the ultrastructural presence of Birbeck-like granules and immunohistochemistry with an antibody against human langerin/CD207 that cross-reacts with salmonid tissues. The appearance of Birbeck-like granules was observed in rainbow trout at 2 weeks post-hatch (PH) Show moreThe ontogeny and disease responses of Langerhans-like cells within lymphoid tissues of Atlantic salmon, Salmo salar, and rainbow trout, Oncorhynchus mykiss, were investigated. These cells were studied in situ with the use of two markers: the ultrastructural presence of Birbeck-like granules and immunohistochemistry with an antibody against human langerin/CD207 that cross-reacts with salmonid tissues. The appearance of Birbeck-like granules was observed in rainbow trout at 2 weeks post-hatch (PH) ...
To evaluate the efficacy of voloxicimab when administered at 15 mg/kg qwk in subjects with platinum-resistant, advanced epithelial ovarian cancer or pri
Gilead Sciences Incs four-drug experimental HIV pill worked as well as a regimen containing protease inhibitor Reyataz in the second pivotal trial of the drug
Wiley Online Library will be unavailable on Saturday 7th Oct from 03.00 EDT / 08:00 BST / 12:30 IST / 15.00 SGT to 08.00 EDT / 13.00 BST / 17:30 IST / 20.00 SGT and Sunday 8th Oct from 03.00 EDT / 08:00 BST / 12:30 IST / 15.00 SGT to 06.00 EDT / 11.00 BST / 15:30 IST / 18.00 SGT for essential maintenance. Apologies for the inconvenience caused ...
BACKGROUND: Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity to PARP inhibitors.. The US Food and Drug Administration approved the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib (Rubraca®, Clovis Oncology, Inc., Boulder, CO) last December as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian carcinoma who have been treated with two or more chemotherapies.[1] The US approval of rucaparib was supported by integrated data from the Study 10 (NCT01482715) and ARIEL2 (NCT01891344) clinical trials.. The phase 2 ARIEL2 study is an ongoing two-part trial designed to examine the efficacy of rucaparib monotherapy as treatment in patients with ovarian carcinoma. Part ...
Although one patient with recurrent ovarian cancer achieved complete response, the first trial of abiraterone conducted in ovarian cancer was halted early due to low response, according to results from the CORAL phase 2 trial.
A second-look procedure is sometimes performed to determine if a cancer patient has responded successfully to a particular treatment. Examples of cancers that are assessed during second-look surgery are ovarian cancer and colorectal cancer. In many cases, before a round of chemotherapy and/or radiation therapy is started, a patient will undergo a surgical procedure called cytoreduction to reduce the size of a tumor. This debulking increases the sensitivity of the tumor and decreases the number of necessary treatment cycles. Following cytoreduction and chemotherapy, a second-look procedure may be necessary to determine if the area is cancer-free. An advantage to second-look surgery following cancer treatment is that if cancer is found, it may be removed during the procedure in some patients. In other cases, if a tumor cannot be entirely removed, the surgeon can debulk the tumor and improve the patients chances of responding to another cycle of chemotherapy. However, second-look surgery cannot ...
Newswise ? Researchers at Moffitt Cancer Center and Duke University Medical Center have conducted a phase I trial of dasatinib, an oral SRC-family tyrosine kinase inhibitor, to determine the maximum tolerated dose when combined with paclitaxel and carboplatin to treat patients with advanced or recurrent ovarian cancer. They found that 150 mg daily in combination…
Surgical eksploration and unilateral salpingo-oophorectomy are the treatment of EST.Does addition hysterectomy and contralateral salpingo-oophorectomy can improve outcome theraphy ? How about the role of second-look laparotomy ? Dysgerminoma is extremely sensitive to chemotherapy, and treatment with chemotherapy cures the majority of patients even with advanced disease. Which regime is much better among VAC, VBP and BEP ?. How about the role of gemcitabine base chemotherapy in refractory germ cell tumors?. Prior to advances in chemotherapy, the prognosis for these aggressive tumours was poor.Over the past decade, new chemotherapeutic regimes have made germ cell tumours among the most highly curable cancers.(4,5,6,7 ...
Lomustin (CCNU) medac is a medicine available in a number of countries worldwide. A list of US medications equivalent to Lomustin (CCNU) medac is available on the Drugs.com website.
Advice about credit score in 12571 on Trulia Voices. Ask a question about real estate , credit score in 12571, and get answers from local experts.

altretaminealtretamine

... is used to ease the symptoms of ovarian cancer. This medication will not treat the cancer itself. Altretamine is ... Altretamine is a cancer medicine that interferes with the growth and spread of cancer cells in the body. ... What is altretamine?. Altretamine is a cancer medicine that interferes with the growth and spread of cancer cells in the body. ... What is the most important information I should know about altretamine?. You should not use altretamine if you have severe ...
more infohttps://www.rexhealth.com/app/healthwise/document.aspx?id=d01372a1

Altretamine - Medical Dictionary / Glossary | MedindiaAltretamine - Medical Dictionary / Glossary | Medindia

Altretamine - An anticancer drug that belongs to the family of drugs called alkylating agents, is clearly explained in ... Altretamine - Glossary. Written & Compiled by Medindia Content Team. Medically Reviewed by The Medindia Medical Review Team on ... Medical Word - Altretamine. Ans : An anticancer drug that belongs to the family of drugs called alkylating agents. ...
more infohttps://www.medindia.net/glossary/altretamine.htm

Altretamine and coccidioidin skin test Drug Interactions - Drugs.comAltretamine and coccidioidin skin test Drug Interactions - Drugs.com

A Moderate Drug Interaction exists between altretamine and coccidioidin skin test. View detailed information regarding this ... Depending on the dose and length of time you have been on altretamine, you may have a reduced response to the skin test. It is ... If you are currently being treated or have recently been treated with altretamine, you should let your doctor know before ...
more infohttps://www.drugs.com/drug-interactions/altretamine-with-coccidioidin-skin-test-136-0-717-0.html

Altretamine - WikipediaAltretamine - Wikipedia

Altretamine (trade name Hexalen) is an antineoplastic agent. It was approved by the U.S. FDA in 1990. It is indicated for use ... Malik IA (2001). "Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer". Jpn. J ... ISBN 978-0-7817-6879-5. Drugs.com: Altretamine Monograph Wiernik, P. H.; Yeap, B.; Vogl, S. E.; Kaplan, B. H.; Comis, R. L.; ... The precise mechanism by which altretamine exerts its anti-cancer effect is unknown but it is classified by MeSH as an ...
more infohttps://en.wikipedia.org/wiki/Altretamine

Altretamine capsulesAltretamine capsules

... What is this medicine?. ALTRETAMINE (al TRET a meen) is a chemotherapy drug. This medicine is used to ... an unusual or allergic reaction to altretamine, other medicines, foods, dyes, or preservatives ...
more infohttp://healthlibrary.brighamandwomens.org/Library/DiseasesConditions/Adult/121,547

Altretamine capsules - AHealthyMe - Blue Cross Blue Shield of MassachusettsAltretamine capsules - AHealthyMe - Blue Cross Blue Shield of Massachusetts

Altretamine capsules. What is this medicine?. ALTRETAMINE (al TRET a meen) is a chemotherapy drug. This medicine is used to ... an unusual or allergic reaction to altretamine, other medicines, foods, dyes, or preservatives ...
more infohttp://www.ahealthyme.com/Library/Encyclopedia/121,547

Altretamine capsules - AHealthyMe - Blue Cross Blue Shield of MassachusettsAltretamine capsules - AHealthyMe - Blue Cross Blue Shield of Massachusetts

Altretamine capsules. What is this medicine?. ALTRETAMINE (al TRET a meen) is a chemotherapy drug. This medicine is used to ... an unusual or allergic reaction to altretamine, other medicines, foods, dyes, or preservatives ...
more infohttp://www.ahealthyme.com/Library/DiseasesConditions/Adult/Endocrinology/121,547

Altretamine | 645-05-6 | B2444 | BioVision, Inc.Altretamine | 645-05-6 | B2444 | BioVision, Inc.

Altretamine is an alkylating agent with antineoplastic and antiproliferative activity. It also acts as a chemosterilant for ... Altretamine is an alkylating agent with antineoplastic and antiproliferative activity. It also acts as a chemosterilant for ...
more infohttps://www.biovision.com/altretamine-22261.html

Altretamine  - Side Effects, Uses, Dosage, Overdose, Pregnancy, Alcohol | The Medicine ShoppeAltretamine - Side Effects, Uses, Dosage, Overdose, Pregnancy, Alcohol | The Medicine Shoppe

Get up-to-date information on Altretamine side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about ... Altretamine is a prescription medication used to treat ovarian cancer in adults. Altretamine belongs to a group of drugs called ... Serious allergic reactions have been reported with altretamine use. Do not take altretamine if you are allergic to any of its ... In the case of altretamine there are no specific foods that you must exclude from your diet when receiving altretamine. ...
more infohttps://www.medicineshoppe.com/altretamine

Altretamine and Etoposide in Treating Patients With HIV-Related Cancer - Full Text View - ClinicalTrials.govAltretamine and Etoposide in Treating Patients With HIV-Related Cancer - Full Text View - ClinicalTrials.gov

Altretamine and Etoposide in Treating Patients With HIV-Related Cancer. The safety and scientific validity of this study is the ... Drug Information available for: Altretamine Etoposide Etoposide phosphate Genetic and Rare Diseases Information Center ... Altretamine. Antineoplastic Agents, Phytogenic. Antineoplastic Agents. Topoisomerase II Inhibitors. Topoisomerase Inhibitors. ... OUTLINE: Patients are treated with altretamine (HMM) and etoposide for 2 weeks followed by 2 weeks of rest. This cycle is ...
more infohttps://clinicaltrials.gov/show/NCT00002936?order=72

Altretamine  | YourCareEverywhereAltretamine | YourCareEverywhere

Altretamine Oral capsule. What is this medicine?. ALTRETAMINE (al TRET a meen) is a chemotherapy drug. This medicine is used to ... an unusual or allergic reaction to altretamine, other medicines, foods, dyes, or preservatives ...
more infohttps://www.yourcareeverywhere.com/article/krames/en/article/health-research/drugs-and-supplements/drug-search/altretamine.html

Altretamine capsulesAltretamine capsules

... What is this medicine?. ALTRETAMINE (al TRET a meen) is a chemotherapy drug. This medicine is used to ... an unusual or allergic reaction to altretamine, other medicines, foods, dyes, or preservatives ...
more infohttp://library.oumedicine.com/Library/DiseasesConditions/Adult/Gynecological/121,547

Altretamine capsules  | YourCareEverywhereAltretamine capsules | YourCareEverywhere

Altretamine capsules. What is this medicine?. ALTRETAMINE (al TRET a meen) is a chemotherapy drug. This medicine is used to ... an unusual or allergic reaction to altretamine, other medicines, foods, dyes, or preservatives ...
more infohttps://www.yourcareeverywhere.com/article/krames/en/article/health-research/drugs-and-supplements/drug-search/altretamine-oral-capsule.html

Altretamine (Oral Route) - Drugs & SupplementsAltretamine (Oral Route) - Drugs & Supplements

Altretamine belongs to the group of medicines called antineoplastics. It is used to treat cancer of the ovaries. It may also be ... Infection - Altretamine may decrease your bodys ability to fight infection * Kidney disease - Effects of altretamine may be ... Before Using Altretamine (Oral Route). In deciding to use a medicine, the risks of taking the medicine must be weighed against ... Altretamine belongs to the group of medicines called antineoplastics. It is used to treat cancer of the ovaries. It may also be ...
more infohttps://pharmacypedia.org/drugs-and-supplements/altretamine-oral-route/

Altretamine (Hexalen) | HemOnc.org - A Hematology Oncology WikiAltretamine (Hexalen) | HemOnc.org - A Hematology Oncology Wiki

Altretamine (Hexalen) patient drug information (UpToDate)[4]. History of changes in FDA indication. *12/26/1990: Initial FDA ... Retrieved from "https://hemonc.org/w/index.php?title=Altretamine_(Hexalen)&oldid=19729" ...
more infohttps://hemonc.org/wiki/Altretamine_

Drug InformationDrug Information

Altretamine Altretamine is an antineoplastic alkylating agent, prescribed for certain types of cancer such as ovarian cancer. ...
more infohttps://www.medindia.net/doctors/drug_information/home.asp

How Chemotherapy Drugs WorkHow Chemotherapy Drugs Work

More than 100 chemotherapy or chemo drugs are used to treat cancer - either alone or in combination with other drugs or treatments. These drugs are very different in their chemical composition, how they are taken, their usefulness in treating specific forms of cancer, and their side effects.
more infohttp://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/how-chemotherapy-drugs-work.html

Compare Current Cancer of the Ovary Drugs and Medications with Ratings & ReviewsCompare Current Cancer of the Ovary Drugs and Medications with Ratings & Reviews

altretamine capsule. On Label. RX. 0 Reviews. Paraplatin 150 mg intravenous powder for solution. On Label. RX. 0 Reviews. ...
more infohttps://www.webmd.com/drugs/2/condition-533/cancer%20of%20the%20ovary

Everything you need to know about oral chemotherapyEverything you need to know about oral chemotherapy

Oral chemotherapy in the form of pills, liquids, or tablets is a treatment option for some types and stages of cancer. Advantages include not having to visit a clinic as frequently, while disadvantages include the risk of making dosing errors when taking the medication at home. Learn more about oral chemotherapy here.
more infohttps://www.medicalnewstoday.com/articles/323482.php?sr

Fergon Advanced Patient Information - Drugs.comFergon Advanced Patient Information - Drugs.com

Detailed drug Information for Fergon. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
more infohttps://www.drugs.com/cons/fergon.html

Patente WO2011099007A1 - Pharmaceutical compositions and methods for the treatment and prevention of ... - Google PatentesPatente WO2011099007A1 - Pharmaceutical compositions and methods for the treatment and prevention of ... - Google Patentes

... altretamine; ambomycin; ametantrone acetate; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa ...
more infohttp://www.google.es/patents/WO2011099007A1?cl=en
  • The precise mechanism by which altretamine exerts its anti-cancer effect is unknown but it is classified by MeSH as an alkylating antineoplastic agent. (wikipedia.org)
  • Altretamine is given in a 28-day treatment cycle, and you may only need to take the medicine during the first 2 or 3 weeks of each cycle. (rexhealth.com)
  • Before you begin treatment with altretamine, you and your doctor should talk about the good this medicine will do as well as the risks of using it. (pharmacypedia.org)
  • Before starting altretamine treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc. (chemocare.com)
  • You should not use altretamine if you have severe nerve problems or severe bone marrow suppression. (rexhealth.com)
  • Your doctor will determine how long to treat you with altretamine. (rexhealth.com)
  • If you are currently being treated or have recently been treated with altretamine, you should let your doctor know before receiving coccidioidin skin test. (drugs.com)
  • What are the possible side effects of altretamine? (rexhealth.com)
  • This is not a complete list of altretamine side effects. (medicineshoppe.com)
  • Although there is no specific information comparing use of altretamine in the elderly with use in other age groups, this medicine is not expected to cause different side effects or problems in older people than it does in younger adults. (pharmacypedia.org)
  • The amount of altretamine that you will receive depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition being treated. (chemocare.com)
  • In the case of altretamine there are no specific foods that you must exclude from your diet when receiving altretamine. (medicineshoppe.com)
  • There is no specific information comparing use of altretamine in children with use in other age groups. (pharmacypedia.org)
  • Administered orally, altretamine is extensively metabolized on first pass, producing primarily mono- and didemethylated metabolites. (wikipedia.org)
  • Altretamine can lower blood cells that help your body fight infections and help your blood to clot. (rexhealth.com)
  • Since the growth of normal body cells may also be affected by altretamine, other effects will also occur. (pharmacypedia.org)